Central banks worldwide continue to view gold as a vital strategic asset for diversification, geopolitical risk management, and financial stability, beyond just an inflation hedge. Poland aims to increase its gold reserves significantly, while Italy and Ghana emphasize gold's role in economic resilience and safe-haven status. The trend of central banks buying gold is expected to persist, driven by concerns over geopolitical uncertainty and the desire to reduce reliance on traditional reserve currencies like the U.S. dollar. Gold's unique status as a physical asset with no credit risk and less exposure to sanctions enhances its appeal in a fragmented global financial landscape.
Central banks' renewed interest in gold reserves provides context for today's market activity on Pluang. For readers following US stocks, here is Pluang's market snapshot as of Oct 07, 2026 01:51 WIB: out of 150 priced US stocks, 96 rose and 54 fell. Notable movers include Novavax Inc (NVAX) at USD 11.07 with a 1-day change of -11.82% and Pluang order activity showing 29% Sell / 71% Buy, Nokia Corp (NOK) at USD 10.86 up 6.42% with 66% Sell / 34% Buy, and Moderna, Inc. (MRNA) at USD 190.40 down 6.30% with 24% Sell / 76% Buy.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
